Molecular endpoints for establishing target engagement by novel idiopathic pulmonary fibrosis therapies Source: Eur Respir J, 53 (3) 1900283; 10.1183/13993003.00283-2019 Year: 2019
The novel oligonucleotide therapeutics PK-7010 for TGF-ß1 ameliorates bleomycin-induced pulmonary fibrosis in mice Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020
αB-crystallin is involved in the process of pulmonary fibrosis Source: Annual Congress 2010 - Emerging mechanisms in lung injury Year: 2010
αB-crystallin is involved in the process of pulmonary fibrosis Source: Annual Congress 2011 - The ageing pulmonary interstitium Year: 2011
iTRAQ-based proteomic analysis reveals mitochondrial 'damage'-associated molecular patterns are involved in pulmonary inflammation in Lypopolysaccharide-induced acute lung injury Source: International Congress 2018 – Role of microbial exposure and inflammation in lung injury Year: 2018
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013
Pharmacological validation of a new IPF bleomycin-induced mouse model Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013
Imaging and molecular biomarkers: a novel approach to screen populations at risk of pulmonary fibrosis? Source: Eur Respir J 2016; 48: 1271-1273 Year: 2016
The potential role of antimicrobial peptides from wasp as regulators of the fibrotic process in idiopathic pulmonary fibrosis. Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019
Identifying pulmonary hypertension in newly recognized interstitial lung diseases – a role of new scoring system Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020
The pathogenesis of pulmonary fibrosis: a moving target Source: Eur Respir J 2013; 41: 1207-1218 Year: 2013
LSC Abstract – A human lung explant model of fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis Source: International Congress 2016 – Molecular immunology of the lung Year: 2016
A longitudinal characterization of lymphangiogenesis in bleomycin-induced pulmonary fibrosis mouse model Source: Annual Congress 2012 - Fibrogenesis between epithelial injury and fibroblast proliferation Year: 2012
PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013
A humanized animal model of pulmonary fibrosis based on cellular senescence Source: Virtual Congress 2020 – Cellular involvement in lung injury Year: 2020
Mitochondrial antiviral signaling protein is crucial for the development of pulmonary fibrosis Source: Eur Respir J, 57 (4) 2000652; 10.1183/13993003.00652-2020 Year: 2021
Evaluation of novel LOXL2-selective inhibitors in models of pulmonary fibrosis Source: International Congress 2017 – Cellular signalling pathways in pulmonary fibrosis Year: 2017
PBI-compound, a novel first-in-class anti-fibrotic compound, inhibits CTGF and collagen production in murine and human fibroblasts, and reduces lung fibrosis in the bleomycin-induced lung fibrosis model Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013
Elucidating signalling pathways in pulmonary hypertension using a microRNA knockout mouse model – In vitro and in vivo data Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015